Mucosamin, a Treatment for Oral Mucositis in Cancer and Diabetes Patients, Launches Sales in Taiwan... "Expecting Rapid Sales Growth This Year"

BigThink Therapeutics, a subsidiary of Kips Biopharma, announced on the 15th that it will officially begin sales of MUCOSAMIN®, an oral mucositis treatment for cancer and diabetes patients for which it holds the Asian distribution rights, in Taiwan. The company expects that expanding overseas sales channels will generate at least an additional 3 billion KRW in annual revenue.

According to BigThink, its local partner, the mid-sized Taiwanese pharmaceutical company CHIFU, obtained approval and sales authorization from the Taiwan Food and Drug Administration (TFDA) on the 3rd of last month for MUCOSAMIN spray and mouthwash formulations. The initial shipment is expected to be finalized as early as next month, with export sales commencing thereafter.

MUCOSAMIN is an oral liquid formulation that helps prevent and treat oral mucositis, which causes pain due to inflammation of the oral mucosa. Oral mucositis frequently occurs in cancer patients whose immune function is compromised by chemotherapy and radiation therapy, as well as in diabetes patients. MUCOSAMIN is known to be superior to existing treatments in shortening the treatment period and alleviating and preventing pain associated with oral mucositis.

MUCOSAMIN was developed by the Italian amino acid specialist pharmaceutical company Professional Dietetics S.p.A. and is currently sold in the European Union (EU), the United Kingdom, Canada, Switzerland, Israel, Iran, India, and other countries.

BigThink holds the Asian distribution rights for MUCOSAMIN (including South Korea, Japan, Thailand, Malaysia, Hong Kong, Singapore, Indonesia, the Philippines, etc.) and expects annual sales exceeding 3 billion KRW through CHIFU in Taiwan. It is also anticipated that approvals and exports will be possible within this year in countries such as Thailand and Malaysia.

Kim Ha-yong, CEO of BigThink, stated, "We will continue to strengthen our diverse oncology lineup, including not only MUCOSAMIN but also the breast cancer treatment 'Nerings' and the neutropenia treatment 'Longquix,' which are currently sold domestically. Through active domestic and international sales activities, this year will be the first year in which our sales exceed 10 billion KRW."